HomeCategoryArhive Signatera - AMS Laborator Genetic

Landmark CIRCULATE-Japan Study Shows Natera’s Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Cancer

Natera, Inc. (NASDAQ: NTRA), a leader in personalized genetic testing and diagnostics, announced new data recently presented on the clinical utility of Signatera, its personalized and tumor-informed molecular residual disease (MRD) test, at the American Society of Clinical Oncology’s 2022 Gastrointestinal Cancers Symposium (ASCO GI). The oral presentation included an updated analysis from the landmark...

How Signatera helps patients during their cancer treatment

Know earlier, it matters! Every person’s cancer is as unique as our fingerprint. Signatera is a residual molecular disease test that is customized for each patient’s set of tumor mutations and can identify earlier than traditional tests if the cancer is still present. How Signatera helps patients during their cancer treatment Anxiety imaging scan is...